La Comercializadora de Servicios Médicos Cubanos, S.A. provides an opportunity for people worldwide battling head and neck cancer. Through a highly specialized and comprehensive therapeutic program, patients can now access an innovative treatment that combines advanced Cuban immunotherapy with the experience of renowned oncology professionals.
This treatment is based on the therapeutic vaccine Nimotuzumab HR3, commercially known as CIMAher®. Developed by the prestigious Center of Molecular Immunology in Cuba, CIMAher® is a humanized monoclonal antibody that has proven effective in treating various forms of cancer. When combined with conventional therapies such as radiotherapy and chemotherapy, the objective response to the disease has shown significant improvement, with success rates ranging from 70% to 100%.
What Makes CIMAher® Unique?
CIMAher® selectively targets tumor cells without affecting normal tissue, allowing its use in combination with other oncology therapies or as a standalone treatment. The HR3 antibody, obtained through genetic engineering, activates the patient's immune system to control the growth of tumor cells, slowing their progression and improving treatment outcomes.
This medication is registered for various indications, including the treatment of nasopharyngeal, esophageal, pancreatic, and non-small cell lung cancers. It is especially recommended for:
Advanced-stage head and neck tumors, in combination with radiotherapy and/or chemotherapy.
High-grade malignant astrocytoma in children refractory to specific oncology treatment, as monotherapy.
Glioblastoma multiforme in adults, in combination with radiotherapy.
Inoperable malignant esophageal tumors of epithelial origin, in combination with radiotherapy and/or chemotherapy.
A Personalized Treatment
The treatment program is carefully tailored to the specific needs of each patient after a thorough evaluation by a multidisciplinary team certified both nationally and internationally. This personalized approach ensures that each patient receives the best possible care, with treatment administered intravenously and requiring accompanied hospitalization.
Access to Treatment
To access this innovative treatment, those interested should contact the Coordination and Processing Center of the Cuban Medical Services Marketer, S.A. via email at smc@smcsalud.cu. After this initial contact, a detailed medical program will be provided, including costs and the treatment plan.
This therapeutic program represents renewed hope for those facing head and neck cancer, offering cutting-edge treatment backed by Cuban medical excellence.
By: M.Sc. Dr. Patricia Alonso Galbán
Communication Specialist at CSMC, S.A.
Innovative CIMAher® Vaccine: Hope for Head and Neck Cancer Patients
Cuba offers a comprehensive and specialized therapeutic program to combat head and neck cancer, combining advanced immunotherapy with the expertise of oncology specialists.
31 August, 2024
by
| No comments yet
CSMC, S.A
x
Sign in to leave a comment
d